Middle East Pharmaceutical Industries Co (SAU:4016) ROCE %: 26.04% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SAU:4016 Middle East Pharmaceutical Industries Co SAU:4016
22 GF Score
Price ﷼60.55
! 3 Warning Signs
View Full Analysis

What is Middle East Pharmaceutical Industries Co ROCE %?

Middle East Pharmaceutical Industries Co SAU:4016 +0.92% 22 ROCE % is 26.04% as of Mar. 2026. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Middle East Pharmaceutical Industries Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 26.04%.

Middle East Pharmaceutical Industries Co  (SAU:4016) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Middle East Pharmaceutical Industries Co ROCE % Related Terms

Middle East Pharmaceutical Industries Co ROCE % Historical Data

* Premium members only.

The historical data trend for Middle East Pharmaceutical Industries Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Middle East Pharmaceutical Industries Co ROCE % Chart

Middle East Pharmaceutical Industries Co Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
23.59 25.13 25.20

Middle East Pharmaceutical Industries Co Quarterly Data
Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.16 26.92 10.38 42.13 26.04
SAU:4016
22GF Score
Middle East Pharmaceutical Industries Co SAU:4016
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Middle East Pharmaceutical Industries Co ROCE % Calculation

Middle East Pharmaceutical Industries Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=108.413/( ( (526.781 - 134.035) + (599.53 - 132.023) )/ 2 )
=108.413/( (392.746+467.507)/ 2 )
=108.413/430.1265
=25.20 %

Middle East Pharmaceutical Industries Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=122.88/( ( (599.53 - 132.023) + (626.478 - 150.285) )/ 2 )
=122.88/( ( 467.507 + 476.193 )/ 2 )
=122.88/471.85
=26.04 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.04% mean?
Middle East Pharmaceutical Industries Co (SAU:4016) has a ROCE % of 26.04% as of Mar. 2026.
Is Middle East Pharmaceutical Industries Co's ROCE % too high?
Middle East Pharmaceutical Industries Co's current ROCE % is 26.04%. The Drug Manufacturers industry median ROCE % is 7.06. Middle East Pharmaceutical Industries Co's value of 26.04% is 268.8% above this industry median. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's ROCE % compare to ZTS and UTHR?
Middle East Pharmaceutical Industries Co's ROCE % of 26.04% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. Middle East Pharmaceutical Industries Co's value of 26.04% is 268.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current ROCE % of 26.04% is 268.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current ROCE % is 26.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current ROCE % of 26.04%. The current ROCE % is 26.04% and 268.8% above the Drug Manufacturers industry median of 7.06. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current ROCE % is 26.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Middle East Pharmaceutical Industries Co Business Description

Address 8146 King Muhammad V, Sulaimaniyah, P.O. Box 4180, Riyadh, SAU, 11491
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score

Get the complete analysis for SAU:4016

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼60.55
Price